Presentation is loading. Please wait.

Presentation is loading. Please wait.

University of Southern California Department of Pharmaceutical Economics and Policy 1540 E. Alcazar Street, CHP 140 Los Angeles, CA 90089-9004 323.442.1460.

Similar presentations


Presentation on theme: "University of Southern California Department of Pharmaceutical Economics and Policy 1540 E. Alcazar Street, CHP 140 Los Angeles, CA 90089-9004 323.442.1460."— Presentation transcript:

1 University of Southern California Department of Pharmaceutical Economics and Policy 1540 E. Alcazar Street, CHP 140 Los Angeles, CA 90089-9004 323.442.1460 http://www.usc.edu/hsc/pharmacy/pharmecon/

2 Department Faculty and Students n 5 faculty (Ahn, Hay, Johnson, McCombs, Nichol) n Recruiting an open level position n 5-8 Masters students n 5-8 Doctoral students n Graduate programs focus on pharmaceutical economics and health services research n Graduate programs include coursework from Economics, Policy Planning and Development, Preventive Medicine (biostatistics)

3 Graduate Courses n Health Care Policy n Applied Health Econometrics n Health Decision Analysis n Research Design and Analysis n Quality of Life and Survey Design n Risks, Probabilities, and Preferences

4 Department Areas of Interest n Decision analysis and modelling n Integrated claims analysis (Medicaid, Medicare, managed care) n Quality of life n Health utility measures (QALYs) n Evaluation of provider and consumer interventions

5 Decision Analytic Modelling n Key Finding: Recently, Department faculty testified at the FDA hearing on converting non-sedating antihistamines from Rx to OTC status. The cost-effectiveness analysis presented demonstrated that the conversion would be cost-saving to the U.S., because of reductions in mortality and morbidity. Subsequent analyses demonstrated that insurance programs should cover both OTC and prescription antihistamines

6 Integrated Claims Analysis n Department faculty recently presented research that showed 25% of Medi-Cal patients with schizophrenia delay initiating drug therapy during the first year of treatment. This results in increased costs of more than $9,400 per patient, primarily due to higher hospital costs of over $5,200 per patient.

7 Burden of Illness, Treatment Patterns, and Costs n Research by Department faculty has shown that treatment for lupus in a Medicaid population varies significantly by ethnicity. In this study, Hispanic patients experienced lower costs than African-American and white patients.

8 Quality of Life n Department faculty have shown that Latinos poorer self-reported visual functioning, and are less likely to seek vision care than whites and blacks.

9 Utility Estimating Procedures n Department faculty have derived utility estimating procedures that will allow investigators to apply a generic health status instrument (the SF-36) in computing quality adjusted life years (QALYs). This technology could potentially expand the use of QALYs in cost-effectiveness analysis dramatically. n Department faculty have also applied conjoint analysis methods to determine patient preferences for treatment alternatives in several key diseases.


Download ppt "University of Southern California Department of Pharmaceutical Economics and Policy 1540 E. Alcazar Street, CHP 140 Los Angeles, CA 90089-9004 323.442.1460."

Similar presentations


Ads by Google